The stock of Aethlon Medical Inc (AEMD) has seen a -14.43% decrease in the past week, with a -44.07% drop in the past month, and a -1.42% decrease in the past quarter. The volatility ratio for the week is 13.13%, and the volatility levels for the past 30 days are at 10.08% for AEMD. The simple moving average for the last 20 days is -26.95% for AEMD’s stock, with a simple moving average of -21.87% for the last 200 days.
Is It Worth Investing in Aethlon Medical Inc (NASDAQ: AEMD) Right Now?
Company’s 36-month beta value is 1.64.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AEMD is 14.14M, and currently, short sellers hold a 3.39% ratio of that floaft. The average trading volume of AEMD on March 17, 2025 was 3.44M shares.
AEMD) stock’s latest price update
Aethlon Medical Inc (NASDAQ: AEMD)’s stock price has gone decline by -11.57 in comparison to its previous close of 0.42, however, the company has experienced a -14.43% decrease in its stock price over the last five trading days. prnewswire.com reported 2025-03-10 that Preclinical Data Suggests Expanded Therapeutic Potential of the Hemopurifier® Beyond Virology and Oncology Results Support Further Evaluation of the Hemopurifier ® as Part of a Machine Perfusion Circuit to Further Assess its Impact on the Function of Retrieved Kidneys SAN DIEGO, March 10, 2025 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases and for use in organ transplantation, today announced the publication of a pre-clinical study in the peer-reviewed journal Transplant Immunology (https://doi.org/10.1016/j.trim.2025.102215) on February 28, 2025, entitled, ” A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys.” Aethlon Medical’s Hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles and life-threatening viruses from blood and other biological fluids.
AEMD Trading at -40.46% from the 50-Day Moving Average
After a stumble in the market that brought AEMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.81% of loss for the given period.
Volatility was left at 10.08%, however, over the last 30 days, the volatility rate increased by 13.13%, as shares sank -40.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.45% lower at present.
During the last 5 trading sessions, AEMD fell by -14.43%, which changed the moving average for the period of 200-days by -11.05% in comparison to the 20-day moving average, which settled at $0.5114. In addition, Aethlon Medical Inc saw -56.56% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for AEMD
The total capital return value is set at -0.0. Equity return is now at value -160.04, with -112.71 for asset returns.
Based on Aethlon Medical Inc (AEMD), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -8.24.
Currently, EBITDA for the company is -11.85 million with net debt to EBITDA at 437.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.77.
Conclusion
In a nutshell, Aethlon Medical Inc (AEMD) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
